Crinetics Pharmaceuticals (CRNX) Earnings Date, Estimates & Call Transcripts → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free CRNX Stock Alerts $44.66 -0.05 (-0.11%) (As of 10:20 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateAug. 13EstimatedActual EPS (May. 9) -$0.93 Missed By -$0.09 Consensus EPS (May. 9) -$0.84 Read Call TranscriptListen to Call Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCRNX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRNX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Smallcaps DailyIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution Crinetics Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.84)($0.68)($0.76)Q2 20242($0.86)($0.71)($0.79)Q3 20242($0.90)($0.74)($0.82)Q4 20242($0.90)($0.77)($0.84)FY 20248($3.50)($2.90)($3.20)CRNX Earnings Date and InformationCrinetics Pharmaceuticals last issued its quarterly earnings data on May 9th, 2024. The reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.09. The business earned $0.64 million during the quarter, compared to the consensus estimate of $0.20 million. Its revenue was down 76.1% on a year-over-year basis. Crinetics Pharmaceuticals has generated ($3.78) earnings per share over the last year (($3.78) diluted earnings per share). Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.53) to ($3.78) per share. Crinetics Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off prior year's report dates.Read More Crinetics Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/13/2024(Estimated)------- 5/9/2024Q1 2024($0.84)($0.93)($0.09)($0.93)$0.20 million$0.64 million 2/28/2024Q4 2023($0.89)($0.90)($0.01)($0.90)$0.20 million- 11/7/2023Q3 2023($0.89)($1.01)($0.12)($1.01)-$0.35 million8/8/2023Q2 2023($0.85)($0.94)($0.09)($0.94)$5.00 million$0.99 million5/4/2023Q1 2023($0.82)($0.85)($0.03)($0.85)$0.63 million$2.68 million2/28/2023Q4 2022($0.82)($0.84)($0.02)($0.84)$0.75 million$0.71 millionIt's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution11/14/2022Q3 2022($0.78)($0.78)-($0.78)$1.00 million$0.46 million8/12/2022Q2 2022($0.62)($0.81)($0.19)($0.81)$1.80 million$0.44 million5/12/2022Q1 2022($0.56)($0.73)($0.17)($0.73)-$3.13 million3/30/2022Q4 2021($0.57)($0.68)($0.11)($0.68)-$1.08 million11/5/2021Q3 2021($0.72)($0.73)($0.01)($0.73)-- 8/9/2021Q2 2021($0.61)($0.70)($0.09)($0.70)--5/6/2021Q1 2021($0.66)($0.69)($0.03)($0.69)-- 3/29/2021Q4 2020($0.58)($0.66)($0.08)($0.66)-- 11/11/2020Q3 2020($0.53)($0.56)($0.03)($0.56)-- 8/7/2020Q2 2020($0.55)($0.53)+$0.02($0.53)--5/8/2020Q1 2020($0.63)($0.71)($0.08)($0.71)-$0.07 million3/9/2020Q4 2019($0.68)($0.60)+$0.08($0.60)$0.30 million$0.32 million11/12/2019Q3 2019($0.5680)($0.60)($0.0320)($0.60)$0.33 million$0.51 million8/13/2019Q2 2019($0.4560)($0.51)($0.0540)($0.51)$0.33 million- Crinetics Pharmaceuticals Earnings - Frequently Asked Questions When is Crinetics Pharmaceuticals's earnings date? Crinetics Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on CRNX's earnings history. Did Crinetics Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Crinetics Pharmaceuticals (NASDAQ:CRNX) missed the analysts' consensus estimate of ($0.84) by $0.09 with a reported earnings per share (EPS) of ($0.93). Learn more on analysts' earnings estimate vs. CRNX's actual earnings. How can I listen to Crinetics Pharmaceuticals's earnings conference call? The conference call for Crinetics Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Crinetics Pharmaceuticals's conference call transcript? The conference call transcript for Crinetics Pharmaceuticals's latest earnings report can be read online. Read Transcript How much revenue does Crinetics Pharmaceuticals generate each year? Crinetics Pharmaceuticals (NASDAQ:CRNX) has a recorded annual revenue of $4.01 million. How much profit does Crinetics Pharmaceuticals generate each year? Crinetics Pharmaceuticals (NASDAQ:CRNX) has a recorded net income of -$214.53 million. CRNX has generated -$3.78 earnings per share over the last four quarters. What is Crinetics Pharmaceuticals's EPS forecast for next year? Crinetics Pharmaceuticals's earnings are expected to decrease from ($3.53) per share to ($3.78) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Avadel Pharmaceuticals Earnings Bicycle Therapeutics Earnings BeiGene Earnings BioMarin Pharmaceutical Earnings Viatris Earnings United Therapeutics Earnings Dr. Reddy's Laboratories Earnings Sarepta Therapeutics Earnings Catalent Earnings Roivant Sciences Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New Heights This page (NASDAQ:CRNX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Crinetics Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.